Pharmacyte Biotech Inc (OTCMKTS:PMCB) a biotech firm in clinical stage developing targeted treatments for diabetes and cancer using its patented Cell-in-a-Box® technology reported that Dr. Gerald W. Crabtree, Ph.D., the Chief Operating Officer, has been featured in the PharmaVOICE Magazine, September edition.
The COO said that they involved thought leaders in both the diabetes and oncology segment for clinical development plans. Their valuable advice will help company steer its treatment development plans in the right direction. The prospect to be interviewed in PharmaVOICE and to talk on this topic enables Pharmacyte to share the advantages of forming an excellent team to advance disease treatments.
Nutra Pharma Corp. (OTCMKTS:NPHC) Reports 1H2015 Financial Numbers
Nutra Pharma Corp. (OTCMKTS:NPHC) filed Form 10-Q wherein it disclosed that net sales stood at $199,061 in 1H2015 compared to $153,658 in the comparable period, a year ago. This jump in sales was a result of the strong sales of Nyloxin. During the period, the cost of sales was $44,675 against $24,967 in 1H2014.
Nutra Pharma stated that direct costs pertaining to Nyloxin manufacturing were included in total cost of sales. The gross profit margin stood at 77.6% in 1H2015 compared to 83.8% in the comparable period, a year ago. The decline in profit margin was a result of jump in the credit card processing fees.
Reliv International, Inc (NASDAQ:RELV) Reports Drop In 2Q2015 Revenue
Reliv International, Inc (NASDAQ:RELV) reported that the revenue dropped 14% to $12.4 million in 1Q2015 compared to revenue recorded in 2Q2014. As per the financial report, the net sale in United States was $9.6 million against $10.8 million in 2Q2014. The company posted net loss of $846,000 in the second quarter of 2015 compared to $289,000 in the comparable quarter in 2014.
In last trading session, the stock price of Pharmacyte gained more than 1% to close the trading session at $0.0974.
